Pharsight

Drugs that contain Olaparib

1. Lynparza patents expiration

LYNPARZA's oppositions filed in EPO
LYNPARZA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7151102 ASTRAZENECA Phthalazinone derivatives
Apr, 2022

(1 year, 10 months ago)

US7981889 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(7 months from now)

US7449464 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(7 months from now)

US8247416 ASTRAZENECA Phthalazinone derivative
Sep, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8912187 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(10 days from now)

US9169235 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(10 days from now)

US9566276 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(10 days from now)

US8143241 ASTRAZENECA DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(3 years from now)

US8071579 ASTRAZENECA DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(3 years from now)

US11633396 ASTRAZENECA Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one
Oct, 2029

(5 years from now)

US8475842 ASTRAZENECA Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
Dec, 2029

(5 years from now)

US8859562 ASTRAZENECA Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(7 years from now)

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of brca mutated ovarian cancer using parp inhibitor; Treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which...

Dosage: CAPSULE;ORAL

How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage

LYNPARZA family patents

Family Patents